randomized trials to optimize treatment of multidrug-resistant tuberculosis随机试验来优化治疗耐多药结核病.pdfVIP

Policy Forum Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis The time for action is now * Carole D. Mitnick , Kenneth G. Castro, Mark Harrington, Leonard V. Sacks, William Burman This is the third of three articles in the November Summary Points The Past 2007 issue on developing new drug treatments for tuberculosis. The time is now right for randomized The history of the development of trials of MDR-TB: current, short-course standardized The Pressing Need for MDR-TB The burden of multidrug-resistant treatment for drug-susceptible TB is Clinical Trials tuberculosis (MDR-TB) is growing, and instructive for developing regimens the standard-of-care treatment is long, to treat MDR-TB. Identified through Drug-resistant strains of Mycobacterium toxic, and frequently unsuccessful. a series of randomized clinical trials, tuberculosis may account for 10% of The need for additional research the short-course approach offered the 8 million new cases of tuberculosis dramatic benefits over earlier (TB) that occur annually. Systematic is clearly illustrated by suboptimal standards of care—treatment duration surveys have been undertaken in treatment outcomes and limited decreased from 24 to six months at least 90 countries. Drug-resistant